SCHEMBL3477005

SCHEMBL3477005

NS(=O)(=O)c1cccc(C(F)(F)F)c1-c1cnns1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STAT3 P40763 1/20 0.36
PTGES2 Q9H7Z7 2/20 0.36
CA2 P00918 3/20 0.35
CA1 P00915 2/20 0.35
CA5A P35218 2/20 0.35
CA9 Q16790 2/20 0.35
CA12 O43570 1/20 0.35
CA4 P22748 1/20 0.35
CA6 P23280 1/20 0.35
CA7 P43166 1/20 0.35
CA14 Q9ULX7 1/20 0.35
CA5B Q9Y2D0 1/20 0.35
LMNA P02545 1/20 0.33
AR P10275 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
SLC22A12 Q96S37 5/20 0.33
CYP2C9 P11712 2/20 0.33
SLC22A6 Q4U2R8 2/20 0.33
SLC22A8 Q8TCC7 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16718822 0.76 PARP1 (0.40) LMNACYP3A4GAA
SCHEMBL3398536 0.73 PTGES2 (0.38) STAT3PTGES2CA2CA1CA5A
SCHEMBL1094712 0.72 ALDH1A1 (0.45) STAT3CA2CA1CA5ACA9
SCHEMBL6917671 0.72 FABP4 (0.44) STAT3PTGES2CA2CA1CA5A
SCHEMBL5762682 0.70 LRRK2 (0.42) STAT3CA2CA1CA9ALDH1A1
SCHEMBL16718782 0.70 ALOX5AP (0.41) PTGES2CA2CA1CA5ACA9
SCHEMBL1093537 0.69 CA1 (0.44) CA2CA1CA9CA12CA4
SCHEMBL302570 0.69 MEN1 (0.56) PTGES2CA2CA1CA5ACA9
SCHEMBL29418255 0.69 MEN1 (0.56) PTGES2CA2CA1CA5ACA9
SCHEMBL2777793 0.68 CA2 (0.47) PTGES2CA2CA1CA5ACA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8907101-B2 Sulfonamide derivatives PFIZER LIMITED (GB) 2014-12-09 US disclosed
US-20130338111-A1 Sulfonamide Derivatives ICAGEN, INC. (US) 2013-12-19 US disclosed
US-20120149679-A1 Sulfonamide Derivatives ICAGEN, INC. 2012-06-14 US disclosed
US-20100197655-A1 SULFONAMIDE DERIVATIVES Pfizer Limited Icagen, Inc. 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197655-A1 SULFONAMIDE DERIVATIVES SULT2A1, SULT1A1, TPST2 STAT3 2721/4885PTGES2 170/4885CA2 302/4885
US-20130338111-A1 Sulfonamide Derivatives SULT2A1, SULT1A1, TPST2 STAT3 2721/4885PTGES2 170/4885CA2 302/4885
US-20120149679-A1 Sulfonamide Derivatives SULT2A1, SULT1A1, TPST2 STAT3 2721/4885PTGES2 170/4885CA2 302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.